Skip to main content

Table 1 Baseline demographics and disease characteristics of all randomized patients

From: Intra-articular injections of sodium hyaluronate (Hyalgan®) in osteoarthritis of the knee. a randomized, controlled, double-blind, multicenter trial in the asian population

 

Total (n = 200)

Hyalgan® (n = 100)

Placebo (n = 100)

p value

Demographic Characteristic

    

Age, mean (SD), yrs

65.0 (8.3)

65.9 (8.1)

64.2 (8.4)

NS

Sex, n (%)

    

   Male

48 (24.0%)

26 (26.0%)

22 (22.0%)

NS

   Female

152 (76.0%)

74 (74.0%)

78 (78.0%)

NS

Weight, mean (SD), kg

62.7 (10.2)

63.3 (11.9)

62.1 (8.3)

NS

Height, mean (SD), cm

156.5 (7.2)

156.8 (7.7)

156.3 (6.7)

NS

BMI, mean (SD), kg/m2

25.6 (3.6)

25.7 (4.3)

25.4 (2.9)

NS

Disease Characteristic

    

Kellgren-Lawrence grade

    

   Grade II (mild), n (%)

119 (59.5%)

59 (59.0%)

60 (60.0%)

NS

   Grade III (moderate), n (%)

81 (40.5%)

41 (41.0%)

40 (40.0%)

NS

Duration of OA, mean (SD), days

427.0 (1022.5)

499.2 (1190.8)

354.8 (820.5)

NS

Clinical Evaluation

    

Pain on 50-foot walking test (VAS 0-100 mm) mean (SD)

46.75 (10.59)

47.85 (10.76)

45.65 (10.36)

NS

WOMAC A-pain (VAS 0-100 mm) mean (SD)

45.56 (12.12)

45.73 (11.17)

45.39 (13.06)

NS

WOMAC C-function(VAS 0-100 mm) mean (SD)

45.99 (12.23)

46.54 (11.31)

45.45 (13.13)

NS

  1. SD, standard deviations.
  2. NS, non-significantly different between treatment groups (P > 0.05)